CIR

NKILT Therapeutics Announces New Scientific Advisory Board Appointments: Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as Advisor

Retrieved on: 
Tuesday, June 6, 2023
Lymphoma, SAB, Drug development, University, Genetic engineering, Therapy, Gene, Stanford University, CSO, Cell therapy, CIR, Center for Cell and Gene Therapy, Baylor University, Cancer, United States Air Force Scientific Advisory Board, NK, Research, Chimera, Doctor of Philosophy, Associate, Acute myeloid leukemia, CAR, AML, MD, Patient, Pathology, Cell, Baylor College of Medicine, American Society of Gene and Cell Therapy, Bone marrow, Alloimmunity, Immunology, Leukemia, Haematopoietic system, Society, Pharmaceutical industry, Medicine

HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.

Key Points: 
  • HOUSTON, June 6, 2023 /PRNewswire/ -- NKILT Therapeutics, a new biotech company committed to the development of novel natural killer (NK) cell therapies, announced today the appointment to their Scientific Advisory Board (SAB) of Saar Gill, MD, PhD, as Chairman and Maksim Mamonkin, PhD, as scientific advisor.
  • Chairman Saar Gill, MD, PhD – Dr. Gill is Associate Professor of Medicine in the division of hematology-oncology at the University of Pennsylvania.
  • He trained in clinical hematology in his native Australia, followed by a postdoctoral fellowship at Stanford University.
  • Since 2011, he has been working on developing genetically engineered immune cells for the treatment of cancer.

(CIR): Johnson Fistel Investigates Proposed Sale of CIRCOR International; Is $49.00 a Fair Price?

Retrieved on: 
Monday, June 5, 2023
Learning, CIR, LLP, Acquisition, Control, KKR, NYSE, Sale, Property management

On June 5, 2023, CIRCOR announced that it has entered into a definitive agreement to be acquired by KKR.

Key Points: 
  • On June 5, 2023, CIRCOR announced that it has entered into a definitive agreement to be acquired by KKR.
  • The investigation concerns whether the CIRCOR board failed to satisfy its fiduciary duties to the Company’s stockholders.
  • First, the investigation includes determining whether the board obtained the best price possible for CIRCOR shares of common stock.
  • Finally, the investigation concerns whether the CIRCOR board adequately pursued alternatives to the proposed acquisition.

CIR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CIRCOR International, Inc. Is Fair to Shareholders

Retrieved on: 
Monday, June 5, 2023
Class Action Lawsuit, Other Professional Services, Legal, Professional Services, CIR, Fraud, Control, KKR, NYSE, Advertising, Sale, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CIRCOR International, Inc. (NYSE: CIR) to investment funds managed by KKR for $49.00 per share in cash is fair to CIRCOR shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CIRCOR International, Inc. (NYSE: CIR) to investment funds managed by KKR for $49.00 per share in cash is fair to CIRCOR shareholders.
  • On behalf of CIRCOR shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

CIRCOR International Enters Definitive Agreement to be Acquired by KKR for $1.6 Billion

Retrieved on: 
Monday, June 5, 2023
Banking, Aerospace, Manufacturing, Professional Services, Asset Management, Other Defense, Defense, Contracts, Insurance, Engineering, Finance, Kirkland & Ellis, CIR, J.P. Morgan & Co., Multimedia, KKR, Ropes & Gray, Citigroup, Control, Growth, Industrial, NYSE, Bank

“Our agreement with KKR marks the successful culmination of a strategic review process conducted by the Board, supported by external advisors and the management team,” said Helmuth Ludwig, CIRCOR’s Board Chair.

Key Points: 
  • “Our agreement with KKR marks the successful culmination of a strategic review process conducted by the Board, supported by external advisors and the management team,” said Helmuth Ludwig, CIRCOR’s Board Chair.
  • KKR is making its investment in CIRCOR through its North America Fund XIII.
  • The Board of Directors of CIRCOR (the “Board”) has unanimously approved the transaction and recommends that CIRCOR shareholders vote in favor of the transaction.
  • Evercore, J.P. Morgan Securities LLC, and Ropes & Gray LLP are serving as advisors to CIRCOR.

CIRCOR International to Participate in the Stifel 2023 Cross Sector Insight Conference

Retrieved on: 
Tuesday, May 30, 2023
Engineering, Defense, Aerospace, Manufacturing, Other Defense, Machinery, CIR, Business development, SVP, Control, Conference, NYSE, Management, Online shopping

CIRCOR International, Inc. (NYSE: CIR) today announced that Tony Najjar, President and Chief Executive Officer, and AJ Sharma, Chief Financial Officer and SVP, Business Development, will participate in a fireside chat and host investor meetings at the Stifel 2023 Cross Sector Insight Conference in Boston.

Key Points: 
  • CIRCOR International, Inc. (NYSE: CIR) today announced that Tony Najjar, President and Chief Executive Officer, and AJ Sharma, Chief Financial Officer and SVP, Business Development, will participate in a fireside chat and host investor meetings at the Stifel 2023 Cross Sector Insight Conference in Boston.
  • The fireside chat will be webcast live at 10:20 a.m.
  • ET Wednesday, June 7, 2023.
  • A webcast of the event will be accessible via the “Investors” section of the CIRCOR website, https://investors.circor.com/ .

Kyriba’s Currency Impact Report: Multinational Corporations Quantify FX Impacts Totaling Near Record $32.21 Billion

Retrieved on: 
Thursday, May 18, 2023
Professional Services, Technology, Finance, Software, Consulting, Banking, CIR, CAD, Risk management, CFOS, EUR, JPY, FX, Treasurer, Yoy, EPS, SVP, SVP Worldwide, Cryptocurrency, Arms industry, Video game

The combined pool of corporations reported $30.22 billion in FX-related headwinds and $1.99 billion in tailwinds in the fourth quarter of 2022.

Key Points: 
  • The combined pool of corporations reported $30.22 billion in FX-related headwinds and $1.99 billion in tailwinds in the fourth quarter of 2022.
  • Out of these impacts, North American companies reported $28.94 billion in headwinds, and European companies reported $1.28 billion in headwinds.
  • “The bottom line is that multinational corporations must have good analytics to understand where their exposures are coming from.
  • To learn more about FX impacts to specific industries and which currencies were most impactful to multinationals, download the May 2023 Kyriba Currency Impact Report here .

Allianz Increases Operating Profit by Almost a Quarter to 3.7 Billion Euros

Retrieved on: 
Friday, May 12, 2023
Professional Services, Insurance, Business, Finance, Asset management, VNB, Allianz, Williams v Natural Life Health Foods Ltd, CIR, Multimedia, Solvency, Financial instrument, NBM, CSM, Roe, EPS, Internal, Engineered wood, Chemical, Gasoline, Clothing, Financial adviser, Bank, Financial services, Security (finance)

1Q 2023: Operating profit jumped 24.2 percent to 3.7 (1Q 2022: 3.0) billion euros.

Key Points: 
  • 1Q 2023: Operating profit jumped 24.2 percent to 3.7 (1Q 2022: 3.0) billion euros.
  • We confirm our full-year outlook of operating profit of 14.2 billion euros, plus or minus 1 billion euros.”
    1Q 2023: Total business volume rose by 11.2 percent to 24.1 (21.7) billion euros.
  • Operating profit surged by 22.7 percent to 1.9 (1.5) billion euros, due to a higher operating insurance service result that was partly offset by a slightly lower operating investment result.
  • Positive net inflows of 14.9 billion euros and favorable market impacts of 42.2 billion euros were partially offset by negative foreign currency translation effects of 23.4 billion euros.

EQS-News: Allianz SE: Allianz increases operating profit by almost a quarter to 3.7 billion euros

Retrieved on: 
Friday, May 12, 2023
Asset management, VNB, Insurance, Williams v Natural Life Health Foods Ltd, CIR, Property & Casualty Management Systems, Finance, Solvency, Financial instrument, NBM, Allianz, CSM, Roe, EPS, Internal, Security (finance), Chemical, Gasoline, Clothing, Financial adviser, Bank, Financial services

1Q 2023: Operating profit jumped 24.2 percent to 3.7 (1Q 2022: 3.0) billion euros.

Key Points: 
  • 1Q 2023: Operating profit jumped 24.2 percent to 3.7 (1Q 2022: 3.0) billion euros.
  • We confirm our full-year outlook of operating profit of 14.2 billion euros, plus or minus 1 billion euros.”
    1Q 2023: Total business volume rose by 11.2 percent to 24.1 (21.7) billion euros.
  • Operating profit increased to 1.3 (0.8) billion euros and benefited in particular from a higher result in the United States.
  • Positive net inflows of 14.9 billion euros and favorable market impacts of 42.2 billion euros were partially offset by negative foreign currency translation effects of 23.4 billion euros.

EQS-News: GRENKE: Operating income rises – net profit in the first quarter of 2023 reduced by extraordinary currency and interest rate effects

Retrieved on: 
Thursday, May 11, 2023
Baden-Baden, Marketing, CIR, Growth, CM2, Consolidated, Film industry, Video game, EUR

This figure already includes the increase in refinancing costs from EUR 13.8 million (Q1 2022) to EUR 24.5 million (Q1 2023).

Key Points: 
  • This figure already includes the increase in refinancing costs from EUR 13.8 million (Q1 2022) to EUR 24.5 million (Q1 2023).
  • In the same period, selling and administrative expenses decreased by 3.7 percent (Q1 2023: EUR 23.9 million versus Q1 2022: EUR 24.8 million).
  • Extraordinary effects from currency valuation of EUR 3.0 million, as well as higher expenses of EUR 1.6 million from the fair value measurement of interest rate derivatives, reduced earnings in the first quarter.
  • Quarterly net profit amounted to EUR 15.9 million (Q1 2022: EUR 20.5 million).

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Retrieved on: 
Monday, May 8, 2023
Volunteering, Institutional review board, Immuron, IMC, US Foods, Campylobacteriosis, Infection, Irritable bowel syndrome, US military watches, Campylobacter, CIR, ETEC, ASX, Enterotoxigenic Escherichia coli, Diarrhea, Judgement, Trial of the century, JHU, Investigational New Drug, Johns Hopkins University, Naval Medical Research Center, Gastroenteritis, Disease, NMRC, Johns, Ethics, Ageing, National Institute of Cholera and Enteric Diseases, FDA, Morale, IND, Food, Safety, Pharmaceutical industry, Vaccine

MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that the US Naval Medical Research Center (NMRC) has received approval from the US Food and Drug Administration (FDA) to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea caused by Campylobacter and ETEC which is now active.

Key Points: 
  • The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea caused by Campylobacter and ETEC which is now active.
  • The first clinical study will be conducted at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the Johns Hopkins Bayview Medical Campus.
  • Infectious diarrhoea is the most common illness reported by travellers visiting developing countries and among US troops deployed overseas.
  • This release has been authorised by the directors of Immuron Limited.